<DOC>
	<DOCNO>NCT00805584</DOCNO>
	<brief_summary>The purpose study test effectiveness side effect desloratadine ( Aerius ) patient hayfever . Patients take desloratadine day 15 day . At end therapy , score severe hayfever symptom respond therapy . Side effect record .</brief_summary>
	<brief_title>Study Nasal Symptom Relief Side Effects Hayfever Patients Treated With Aerius ( Desloratadine ) ( P03442 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<criteria>Subjects must demonstrate willingness participate study comply procedure sign write informed consent . Subjects must &gt; =18 year age , either sex race . Women childbearing potential ( include woman less 1 year postmenopausal woman become sexually active ) must use agree use acceptable method birth control . Women currently sexually active must agree consent use sort contraception become sexually active participate study . Subjects must general good health , i.e. , must free clinically significant disease ( SAR ) would interfere study evaluation . Subjects must understand able adhere dose visit schedule , agree report concomitant medication adverse event Investigator designee . Subjects must least positive history , selfreported history sign symptom acceptable , recur seasonal allergic rhinitis Subjects must clinically symptomatic SAR Visit 2 ( Baseline ) : total ( nasal + nonnasal ) symptom score must &gt; =8 point nasal congestion score &gt; =2 , nonnasal symptom score must &gt; =2 . Subjects may reschedule two additional time qualify visit meet minimum symptom score . Women childbearing potential must negative pregnancy history Visit 1 . Women pregnant nursing . Subjects observed designate washout period prohibit medication . Subjects asthma require chronic use inhale systemic corticosteroid . Subjects current history frequent , clinically significant sinusitis chronic purulent postnasal drip . Subjects rhinitis medicamentosa . Subjects upper respiratory tract sinus infection require antibiotic therapy within 14 day prior Visit 1 ( Screening / Consent ) , subject viral upper respiratory infection within 7 day prior Visit 1 . Subjects nasal structural abnormality , include nasal polyp mark septal deviation , significantly interfere nasal airflow . Subjects , opinion Investigator , dependent upon nasal , oral ocular decongestant , nasal topical antihistamine , nasal steroid . Subjects history hypersensitivity desloratadine excipients . Subjects staff personnel directly involve administration study . Subjects current evidence clinically significant hematopoetic , metabolic , cardiovascular , immunologic , neurologic , hematologic , gastrointestinal , hepatic , renal , psychiatric , cerebrovascular , respiratory disease , disorder , judgment Investigator , may interfere study evaluation affect subject safety . Subject take prohibited drug list study protocol exclude participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>